Neo Biopharm ApS: Financial statements 2024
CVR: 42875708
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Neo Biopharm ApS (CVR 42875708) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 206,139 and a net result of DKK 157,190 compared with DKK 243,802 the year before. That is a decrease of 61% compared with the year before. Equity in the 2024 report amounted to DKK 2,265,898. The solvency ratio was 90.2%.
- Gross Profit
- DKK 206,139
- Profit/Loss
- DKK 157,190
- Equity
- DKK 2,265,898
- Total Assets
- DKK 2,513,272
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Neo Biopharm ApS has published its annual report for 2023. Gross profit came to DKK 528,359, and the net result was DKK 243,802.
As of March 1, 2024, Jakob Juul Rasmussen is registered as director of Neo Biopharm ApS.
As of March 1, 2024, Maryam Badri has stepped down as director of Neo Biopharm ApS.
About Neo Biopharm ApS
Neo Biopharm ApS is a Danish company of the type Anpartsselskab based in Hellerup, founded in 2021. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Amirhossein Saadatirad and Jakob Juul Rasmussen. The company is owned by Maryam Badri. In 2025, the company reported a gross profit of DKK -357,308 and a net result of DKK -271,403 compared with DKK 157,190 the year before. Equity in the 2025 report amounted to DKK 1,994,496.